PROTEOSTASIS THERAPEUTICS, INC. News (NASDAQ:PTI)

DateTimeSource
Headline
02/08/20187:00AMGLOBEProteostasis Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced... More...>>
01/08/20187:00AMGLOBEProteostasis’ Proprietary Triple Combination Therapy Study Protocol Receives Endorsement and High Strategic Fit Score from ...
CAMBRIDGE, Mass., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, announced today... More...>>
12/21/20174:50PMGLOBEProteostasis Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option...
CAMBRIDGE, Mass., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, announced today... More...>>
12/15/201710:00AMGLOBEProteostasis Therapeutics, Inc. (Nasdaq:PTI) to Ring The Nasdaq Stock Market Opening Bell
ADVISORY, Dec. 15, 2017 (GLOBE NEWSWIRE) -- What: Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, will visit the Nasdaq... More...>>
12/13/20178:31PMGLOBEProteostasis Therapeutics Prices Public Offering of Common Stock
CAMBRIDGE, Mass., Dec. 13, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, announced today... More...>>
12/12/20174:02PMGLOBEProteostasis Therapeutics Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (Nasdaq:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, announced today... More...>>
12/11/20174:21PMGLOBEProteostasis Therapeutics Announces Positive Clinical Results from Studies of PTI-428, PTI-801 and PTI-808 in Healthy Volunt...
CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced... More...>>
11/14/20175:40PMGLOBEProteostasis Therapeutics Reports Third Quarter 2017 Results and Provides CF Portfolio Update
Preliminary Data from PTI-428 + Orkambi 28 Day Clinical Study on Track for Q4 2017 Initial Data from PTI-801 + Orkambi 14 Day Clinical Trial Anticipated in Q4 2017 Initial Data from PTI-808 SAD and MAD HV 7 day Study Anticipated in Q4 2017 Initial Data from PTI-808 + PTI-801 + PTI-428 coadministration HV 7 day Study... More...>>
10/31/20174:05PMGLOBEProteostasis Therapeutics Focuses on Research and Development of CF Drug Candidates and Astellas Pharma Collaboration Program...
CAMBRIDGE, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis (CF), today announced that the Company has initiated a strategic prioritization... More...>>
07/31/20174:16PMGLOBEProteostasis Therapeutics Announces Progression of PTI-428 and PTI-801 to Longer Duration Studies in CF Subjects
PTI-801 Moving to 14 Day Proof of Concept Study in CF Subjects on Orkambi®PTI-428 Continues to Enroll 28 Day Proof of Concept Study in CF Subjects on Orkambi®PTI-808 Investigational New Drug Application Now Active; Phase 1 Study in Healthy Volunteers Initiated CAMBRIDGE, Mass., July 31, 2017 (GLOBE NEWSWIRE) -- Proteostasis... More...>>
07/31/20174:15PMGLOBEProteostasis Appoints Helen M. Boudreau as Chief Financial Officer
CAMBRIDGE, Mass., July 31, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis (CF), today announced that it has appointed Helen M. Boudreau as the Company’s... More...>>
06/29/20177:00AMGLOBEProteostasis Therapeutics Reports Preliminary Data from Phase 1 Study of PTI-428 in Patients with Cystic Fibrosis
CAMBRIDGE, Mass., June 29, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis (CF), today announced preliminary data from the Multiple Ascending Dose... More...>>
06/23/20177:00AMGLOBEProteostasis Therapeutics Files Investigational New Drug Application for PTI-808, Cystic Fibrosis Potentiator
CAMBRIDGE, Mass., June 23, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis (CF), today announced that the Company has filed an Investigational New... More...>>
06/07/20177:00AMGLOBEProteostasis Therapeutics Announces Clinical and Regulatory Progress Across Pipeline Programs
CAMBRIDGE, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis (CF), today announced updates across the Company’s later stage development... More...>>
03/30/20174:30PMGLOBEProteostasis Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update
PTI-801 Receives FDA Fast Track Designation; Phase 1 Study Underway IND Submission for PTI-808 Planned for 2Q17 Phase 1 Study of PTI-428 Updated and Ongoing; Results Expected 2Q17 CAMBRIDGE, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small... More...>>
11/10/20167:00AMGLOBEProteostasis Therapeutics Reports Third Quarter 2016 Financial Results
CAMBRIDGE, Mass., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis, today reported financial results for the third quarter ended September... More...>>
10/28/201611:45AMBWSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Involving Possible Securities Fraud Violat...
Levi & Korsinsky, LLP announces that it has commenced an investigation of Proteostasis Therapeutics, Inc. (“Proteostasis Therapeutics” or the “Company”) (NASDAQ:PTI) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors. On October 27, 2016, Proteostasis... More...>>
10/26/20164:05PMGLOBEProteostasis Therapeutics Announces Conference Call to Provide Clinical and Scientific Update at 30th Annual North American C...
CAMBRIDGE, Mass., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis, today announced that the company will hold a conference call on Thursday... More...>>
09/28/20167:30AMGLOBEProteostasis Therapeutics Appoints Naimish Patel, M.D., C.M., and Elizabeth Tullis, M.D., FRCPC, to its Clinical Advisory Boa...
CAMBRIDGE, Mass., Sept. 28, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing such as cystic fibrosis (CF), today announced the appointment of Naimish Patel, M.D., C.M., and... More...>>
09/22/20167:30AMGLOBEProteostasis Therapeutics Announces Scientific Presentations on New Data at 30th Annual North American Cystic Fibrosis Confer...
CAMBRIDGE, Mass., Sept. 22, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by dysfunctional protein processing, such as cystic fibrosis (CF), today announced that company scientists will present data from... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V:us D:20180225 21:30:59